| Disease | THE EFFICACY OF FOUR CHOLINESTERASE INHIBITORS (TACRINE, DONEPEZIL, RIVASTIGMINE, METRIOFONATE) AND GINKGO SPECIAL EXTRACT EGB 761 IN ALZHEIMER'S DISEASE WERE COMPARED. THE DIFFERENCES IN THE EFFECT OF THE ACTIVE SUBSTANCE AND PLACEBO ON
COGNITION WERE MEASURED ON THE ADAS-COG SCALE, TAKING INTO ACCOUNT THE DIFFERENT DEGREES OF DEMENTIA IN THE VARIOUS STUDIES AND THE DROPOUT RATE DUE TO ADVERSE DRUG REACTIONS. EFFICACY, EXPRESSED AS THE DELAY IN SYMPTOM PROGRESSION OR THE
DIFFERENCE IN RESPONSE RATE BETWEEN ACTIVE SUBSTANCE AND PLACEBO SHOWED NO MAJOR DIFFERENCES BETWEEN THE FOUR CHOLINESTERASE INHIBITORS AND THE GINKGO SPECIAL EXTRACT. ONLY TACRINE EXHIBITED A HIGH DROPOUT RATE DUE DUE TO ADVERSE DRUG REACTIONS.
IN VIEW OF THIS, THE SUBJECT OF NEW PRESCRIPTIONS SHOULD BE CRITICALLY REVIEWED. SECOND-GENERATION CHOLINESTERASE INHIBITORS (DONEPEZIL, RIVASTIGMINE, METRIFONATE) AND GINKGO SPECIAL EXTRACT EGB 761 SHOULD BE CONSIDERED EQUALLY EFFECTIVE
IN THE TREATMENT OF MILD TO MODERATIVE ALZHEIMER'S DEMENTIA.
A COMMERCIAL PRODUCT, EGB-761, WAS USED. |